Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: XIAFLEX Collagenase injection Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

NCT01674634
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
XIAFLEX / XIAPEX
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Not listed Phase 4 Interventional

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

NCT02249052
View directory record Official record
Conditions
Lipoma
Interventions
AA4500, placebo
Drug
Lead sponsor
Gerut, Zachary, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Hewlett, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

NCT03815331
View directory record Official record
Conditions
Peyronie's Disease (PD)
Interventions
Xiaflex®, Aveed
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

NCT00528606
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221623
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.

NCT05026216
View directory record Official record
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females

NCT05309525
View directory record Official record
Conditions
Cellulite
Interventions
Collagenase Clostridium Histolyticum-Aaes, Lysteda 650 MG Oral Tablet
Drug
Lead sponsor
Luxurgery
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 17, 2026, 6:34 AM EDT
Withdrawn Phase 2 Interventional

Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)

NCT00261196
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
Collagenase
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 17, 2026, 6:34 AM EDT
Completed No phase listed Observational

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

NCT05249257
View directory record Official record
Conditions
Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of AA4500 in Men With Peyronie's Disease

NCT01243411
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

NCT03329989
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
Collagenase Clostridium Histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • Huntington Beach, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 17, 2026, 6:34 AM EDT
Withdrawn Not applicable Interventional

Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction

NCT05646602
View directory record Official record
Conditions
Peyronie Disease, Penile Curvature, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Duolith SD1 T-TOP
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528840
View directory record Official record
Conditions
Advanced Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Burbank, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

NCT02193828
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Tucson, Arizona • Encinitas, California • Greenbrae, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

NCT02006719
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
Collagenase Clostridium Histolyticum, Placebo
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 1Phase 2 Interventional

Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand

NCT00261209
View directory record Official record
Conditions
Adhesion of Flexor Tendon of Hand
Interventions
Collagenase, Collagenase injection
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 17, 2026, 6:34 AM EDT
Not yet recruiting Early Phase 1 Interventional

Collagenase Injection for Contracture Management

NCT07693556
View directory record Official record
Conditions
Contracture
Interventions
Active XIAFLEX Collagenase injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 17, 2026, 6:34 AM EDT
Active, not recruiting Phase 4 Interventional

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

NCT05777031
View directory record Official record
Conditions
Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male
Interventions
Collagenase Clostridium Histolyticum (CCH)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Administration of Two Injections for Multiple Dupuytren's Contractures

NCT01407068
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
AA4500 collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

NCT01613313
View directory record Official record
Conditions
Lipoma
Interventions
Collagenase Clostridium Histolyticum
Drug
Lead sponsor
Zachary Gerut
Individual
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hewlett, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 17, 2026, 6:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb

NCT01265420
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Injectable clostridial collagenase
Biological
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Indianaplis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 17, 2026, 6:34 AM EDT